| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | 7,509 | 34,590 |
| Stock-based compensation expense | 14,556 | 10,192 |
| Depreciation | 6,268 | 4,173 |
| Net accretion of discounts/premiums on marketable securities | -2,232 | -1,766 |
| Gain on disposal of property and equipment | 59 | 59 |
| Other receivables | 4,792 | 2,196 |
| Accounts receivable | - | 0 |
| Prepaid expenses and other assets | 772 | 1,713 |
| Accounts payable | -3,096 | -11,976 |
| Accrued expenses and other current liabilities | -883 | -5,077 |
| Defined benefit plan liability | -1,192 | -957 |
| Right-of-use assets and operating lease liabilities | -781 | -427 |
| Deferred revenue | 3,306 | -106,910 |
| Net cash provided by (used in) operating activities | 20,216 | -80,212 |
| Purchases of property and equipment | 3,933 | 3,282 |
| Purchases of marketable securities | 223,016 | 157,047 |
| Proceeds from maturities of marketable securities | 190,182 | 85,424 |
| Net cash used in investing activities | -36,767 | -74,905 |
| Proceeds from sale of common stock pursuant to the at-the-market sales agreement, net of underwriter's discount of 29 | 0 | 0 |
| Proceeds from underwritten public offering , net of underwriter's discount of 3,000 | 0 | 0 |
| Proceeds from the issuance of pre-funded warrants | 0 | 0 |
| Payment of common stock and pre-funded warrant issuance costs | 0 | 0 |
| Proceeds from exercise of employee stock options | 362 | 14 |
| Proceeds from employee stock purchase plan | 365 | 365 |
| Net cash provided by financing activities | 727 | 379 |
| Net decrease in cash, cash equivalents and restricted cash | -15,824 | -154,738 |
| Cash and cash equivalents at beginning of period | 229,117 | - |
| Cash and cash equivalents at end of period | 213,293 | - |
Monte Rosa Therapeutics, Inc. (GLUE)
Monte Rosa Therapeutics, Inc. (GLUE)